论文部分内容阅读
目的:对乙肝相关性肝细胞癌术患者采用抗病毒的治疗措施,探讨其对患者术后复发情况的临床应用价值。方法:抽取2012年1月-2014年12月我院收治的84例乙肝相关性肝细胞癌患者作为研究对象,依据患者的入院顺序将其随机分为两组,每组42例,其中观察组患者术后予以抗病毒方案进行肝内复发的预防治疗措施,对照组患者术后未对其进行抗病毒预防措施。观察两组患者术后发生肝内复发的发生率以及生存时间。结果:两组患者术后1年以及2年的累计复发率无显著差异,且观察组低于对照组,组间比较无统计学意义(P>0.05);观察组患者的3年累计复发率71.4%明显低于对照组的90.5%,组间比较差异具有统计学意义(P<0.05);观察组患者的生存时间(34.5±2.3)个月明显高于对照组的(24.6±2.1)个月,组间比较差异具有统计学意义(P<0.05)。结论:对乙肝相关性肝细胞癌患者采用射频消融术后采用抗病毒的预防措施,可明显减少其肝内复发率,有效延长了生存时间,达到了较好的预后,可积极推广。
Objective: To treat patients with hepatitis B-related hepatocellular carcinoma by antiviral therapy and explore its clinical value in the patients with postoperative recurrence. Methods: From January 2012 to December 2014, 84 patients with hepatitis B-related hepatocellular carcinoma who were admitted to our hospital from January 2012 to December 2014 were selected as the research objects. According to the patients’ admission order, they were randomly divided into two groups, 42 cases in each group. The observation group Patients were treated with anti-virus regimen for prevention and treatment of intrahepatic recurrent disease. Patients in the control group were not given antiviral prophylaxis after operation. The incidence of intrahepatic recurrence and survival time in both groups were observed. Results: There was no significant difference in the cumulative recurrence rate between the two groups at 1 year and 2 years after operation, and the observation group was lower than the control group. There was no significant difference between the two groups (P> 0.05). The 3-year cumulative recurrence rate 71.4% in the control group was significantly lower than 90.5% in the control group (P <0.05). The survival time in the observation group (34.5 ± 2.3) months was significantly higher than that in the control group (24.6 ± 2.1) Month, the difference between the groups was statistically significant (P <0.05). Conclusion: The anti-virus preventive measures after radiofrequency catheter ablation in patients with hepatitis B-related hepatocellular carcinoma can significantly reduce the intrahepatic recurrence rate, effectively prolong the survival time, achieve a better prognosis, and can be actively promoted.